NEPHROS, INC. Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)
NEPHROS, INC. (NEPH) reported Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) of $11.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease · last filed 2021-03-01
- NEPHROS, INC. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2020 was $11.00K, a 10.00% increase from fiscal 2019.
- NEPHROS, INC. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2019 was $10.00K, a 28.57% decline from fiscal 2018.
- NEPHROS, INC. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2018 was $14.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 12 month |
|---|---|
| 2020-12-31 | $11.00K 10-K · filed 2021-03-01 |
| 2019-12-31 | $10.00K 10-K · filed 2020-02-27 |
| 2018-12-31 | $14.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| ACCURAY INC (ARAY) | United States | $0.027B | -0.63 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 |